Biotech RadarJobs updated

COMPANY

Viking Therapeutics

HQ: San Diego, CA source · vikingtherapeutics.com ↗ · West Coast

Clinical Phase 3

14 open jobs · last seen Oct 23, 2026 · 13 sources

Viking Therapeutics is developing treatments for obesity. From company website Source · Oct 12, 2026

Keywords: metabolic obesity adrenoleukodystrophy Weight Loss Hip Fractures NASH Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) NASH - Nonalcoholic Steatohepatitis Hyperlipidemia NAFLD VK2735 VK2809 VK5211 VK0214

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

14Open jobs13Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Engineer, Sterile Drug ProductViking Therapeutics, Inc.Oct 22, 2026Oct 23, 2026
Director, Clinical QualityViking Therapeutics, Inc.Oct 22, 2026Oct 23, 2026
Program Manager, CMCViking Therapeutics, Inc.Oct 21, 2026Oct 22, 2026
Director/Senior Director, Preclinical Pharmacology/ToxicologyViking Therapeutics, Inc.Oct 3, 2026Oct 16, 2026
Director, Regulatory Affairs EUViking Therapeutics Ireland Ltd., RemoteOct 2, 2026Oct 16, 2026

See all 14 jobs

Timeline

  1. Trial start 3: Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) source ↗
  2. Trial start 3: Oral VK2735 for Weight Management Phase 3 (SUNRISE 1) source ↗
  3. Trial start 1: A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities source ↗
  4. Trial start 1: A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities source ↗
  5. Trial start 3: VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) source ↗
  6. Trial start 3: VK2735 for Weight Management Phase 3 source ↗
  7. Trial start 2: VK2735 for Weight Management Phase 2 (Venture Oral Dosing) source ↗
  8. Trial start 2: VK2735 for Weight Management Phase 2 source ↗
  9. Trial start 1: Phase 1 Study to Evaluate the Safety and Tolerability of VK2735 source ↗
  10. Trial start Phase 1: A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN source ↗
  11. Trial start Phase 2: A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH source ↗
  12. Trial start Phase 2: Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease source ↗
  13. Trial start Phase 2: Acute Hip Fracture Study in Patients 65 Years or Greater source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 13

RecordTitlePhaseStatusStartPrimary completion
NCT07868835Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)3Not yet recruitingOct 15, 20262028-07 (estimated)
NCT07868939Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)3Not yet recruitingOct 16, 20262028-10 (estimated)
NCT07846033A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities1RecruitingJul 6, 2026Oct 2, 2026 (estimated)
NCT07838740A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities1RecruitingNov 18, 20252027-05 (estimated)
NCT07104383VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)3Active, not recruitingJun 23, 2025Jul 1, 2027 (estimated)
NCT02578095Acute Hip Fracture Study in Patients 65 Years or GreaterPhase 2CompletedOct 30, 2015Nov 15, 2017 (actual)
NCT07104500VK2735 for Weight Management Phase 33Active, not recruitingJun 23, 2025Jul 1, 2027 (estimated)
NCT06828055VK2735 for Weight Management Phase 2 (Venture Oral Dosing)2CompletedDec 18, 2024Jun 24, 2025 (actual)
NCT05203237Phase 1 Study to Evaluate the Safety and Tolerability of VK27351CompletedDec 14, 2021Nov 4, 2024 (actual)
NCT04973657A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMNPhase 1CompletedJun 22, 2021Oct 9, 2024 (actual)
NCT06068946VK2735 for Weight Management Phase 22CompletedAug 31, 2023Feb 27, 2024 (actual)
NCT04173065A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASHPhase 2CompletedNov 15, 2019May 15, 2023 (actual)
NCT02927184Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver DiseasePhase 2CompletedSep 28, 2016Mar 26, 2019 (actual)

Open jobs 14

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Engineer, Sterile Drug ProductViking Therapeutics, Inc.Oct 22, 2026Oct 23, 2026Not stated
Director, Clinical QualityViking Therapeutics, Inc.Oct 22, 2026Oct 23, 2026Not stated
Program Manager, CMCViking Therapeutics, Inc.Oct 21, 2026Oct 22, 2026Not stated
Director/Senior Director, Preclinical Pharmacology/ToxicologyViking Therapeutics, Inc.Oct 3, 2026Oct 16, 2026Senior
Director, Regulatory Affairs EUViking Therapeutics Ireland Ltd., RemoteOct 2, 2026Oct 16, 2026Senior
Associate Medical DirectorViking Therapeutics, Inc.Sep 30, 2026Oct 16, 2026Senior
Senior Director, Program ManagementViking Therapeutics, Inc.Sep 25, 2026Oct 16, 2026Senior
Medical WriterViking Therapeutics, Inc.Sep 8, 2026Oct 16, 2026Mid
Manager, GMP Quality OperationsViking Therapeutics, Inc.Sep 8, 2026Oct 16, 2026Senior
Director, Regulatory AffairsRemoteAug 24, 2026Oct 16, 2026Senior
Senior Clinical Trial ManagerViking Therapeutics, Inc.Aug 22, 2026Oct 16, 2026Senior
Clinical Supply Chain CoordinatorViking Therapeutics, Inc.Aug 14, 2026Oct 16, 2026Entry
Associate Director, Medical Writing & Scientific CommunicationsViking Therapeutics, Inc.Aug 3, 2026Oct 16, 2026Senior
Stability Coordinator/ManagerViking Therapeutics, Inc.Jul 17, 2026Oct 16, 2026Mid

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Viking Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback